<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00075491</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02566</org_study_id>
    <secondary_id>ID02-701</secondary_id>
    <secondary_id>R21CA097767</secondary_id>
    <secondary_id>CDR0000346722</secondary_id>
    <nct_id>NCT00075491</nct_id>
  </id_info>
  <brief_title>Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme</brief_title>
  <official_title>A Phase II Evaluation With Correlative Studies Of Fenretinide (NSC 374551-4HPR) As A Single Agent In The Treatment Of Adult Patients With Recurrent Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase II trial is studying how well neoadjuvant and adjuvant fenretinide&#xD;
      works compared to adjuvant fenretinide alone in treating patients who are undergoing surgical&#xD;
      resection for recurrent glioblastoma multiforme. Chemotherapy drugs, such as fenretinide,&#xD;
      work in different ways to stop tumor cells from dividing so they stop growing or die. Giving&#xD;
      chemotherapy before surgery may shrink the tumor so that it can be removed. Giving&#xD;
      chemotherapy after surgery may kill any remaining tumor cells. It is not yet known whether&#xD;
      neoadjuvant and adjuvant fenretinide is more effective than adjuvant fenretinide alone&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Compare the efficacy of neoadjuvant and adjuvant fenretinide vs adjuvant fenretinide&#xD;
      alone, in terms of 6-month progression-free survival, in patients with recurrent glioblastoma&#xD;
      multiforme undergoing surgical resection II. Correlate the serum and glioma tissue&#xD;
      pharmacology of this drug with clinical response in patients treated with these regimens.&#xD;
&#xD;
      III. Determine whether this drug induces apoptosis in glioma tissue in patients treated with&#xD;
      these regimens.&#xD;
&#xD;
      IV. Correlate the apoptotic index with tissue and serum concentration and clinical response&#xD;
      in patients treated with these regimens.&#xD;
&#xD;
      V. Compare radiological response, overall survival, and unexpected toxicity in patients&#xD;
      treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      Arm I: Patients receive neoadjuvant oral fenretinide twice daily for 1 week and then undergo&#xD;
      surgical resection.&#xD;
&#xD;
      Arm II: Patients undergo surgical resection.&#xD;
&#xD;
      Beginning two weeks after surgery, all patients receive adjuvant oral fenretinide twice daily&#xD;
      on weeks 1 and 4. Courses repeat every 6 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 21-46 patients (10-23 per treatment arm) will be accrued for&#xD;
      this study within 7-46 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>December 2003</start_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma and tissue concentrations of fenretinide and its metabolite, 4-MPR using high-performance liquid chromatography (HPLC) assay</measure>
    <time_frame>At baseline, and at 1, 7, 14, and 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor apoptotic index after fenretinide treatment by immunohistochemistry</measure>
    <time_frame>At the time of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between tumor apoptotic index with serum and tissue fenretinide levels</measure>
    <time_frame>At the time of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of time to progression with drug levels and apoptotic index</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fenretinide effects on retinol, RBP, retinoid receptor levels and IGF-1</measure>
    <time_frame>Up to 21 days (course 1 and 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fenretinide activity using magnetic resonance spectroscopy (MRS)</measure>
    <time_frame>At the time of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unexpected toxicity associated with fenretinide as assessed by CTC version 3.0</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Recurrent Adult Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Arm I (fenretinide, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive neoadjuvant oral fenretinide twice daily for 1 week and then undergo surgical resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (surgery)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo surgical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenretinide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (fenretinide, surgery)</arm_group_label>
    <other_name>fenretinimide</other_name>
    <other_name>McN-R-1967</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Arm I (fenretinide, surgery)</arm_group_label>
    <arm_group_label>Arm II (surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (fenretinide, surgery)</arm_group_label>
    <arm_group_label>Arm II (surgery)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (fenretinide, surgery)</arm_group_label>
    <arm_group_label>Arm II (surgery)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed glioblastoma multiforme after initial tumor resection&#xD;
&#xD;
          -  Radiologically evident recurrent tumor after prior radiotherapy OR after treatment for&#xD;
             no more than 2 prior relapses&#xD;
&#xD;
               -  Enhancing or nonenhancing recurrent disease by MRI&#xD;
&#xD;
          -  No progressive symptoms requiring urgent surgery&#xD;
&#xD;
          -  Performance status - Karnofsky 70-100%&#xD;
&#xD;
          -  More than 8 weeks&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  PT/PTT no greater than upper limit of normal&#xD;
&#xD;
          -  SGPT no greater than 2.5 times normal&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times normal&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  BUN no greater than 1.5 times normal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 2 months&#xD;
             after study participation&#xD;
&#xD;
          -  Amylase and lipase normal&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other disease that would obscure toxicity or dangerously alter drug metabolism&#xD;
&#xD;
          -  No other concurrent serious medical illness&#xD;
&#xD;
          -  Not at risk from any study treatment delays&#xD;
&#xD;
          -  Able to swallow fenretinide capsules&#xD;
&#xD;
          -  Recovered from all prior chemotherapy&#xD;
&#xD;
          -  Approximately 2 weeks since prior vincristine&#xD;
&#xD;
          -  Approximately 6 weeks since prior nitrosoureas&#xD;
&#xD;
          -  Approximately 3 weeks since prior procarbazine&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 week since prior vitamin A&#xD;
&#xD;
          -  At least 1 week since prior isotretinoin (Accutane®)&#xD;
&#xD;
          -  No concurrent vitamin A during and for 2 weeks after study participation&#xD;
&#xD;
          -  No concurrent antioxidants (e.g., ascorbic acid or vitamin E)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vinay K. Puduvalli</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>January 9, 2004</study_first_submitted>
  <study_first_submitted_qc>January 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2004</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenretinide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

